BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19687312)

  • 1. Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia.
    Natkunam Y; Tedoldi S; Paterson JC; Zhao S; Rodriguez-Justo M; Beck AH; Siebert R; Mason DY; Marafioti T
    Am J Clin Pathol; 2009 Sep; 132(3):361-71. PubMed ID: 19687312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23).
    Morito N; Yoh K; Maeda A; Nakano T; Fujita A; Kusakabe M; Hamada M; Kudo T; Yamagata K; Takahashi S
    Cancer Res; 2011 Jan; 71(2):339-48. PubMed ID: 21224354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
    Chesi M; Bergsagel PL; Shonukan OO; Martelli ML; Brents LA; Chen T; Schröck E; Ried T; Kuehl WM
    Blood; 1998 Jun; 91(12):4457-63. PubMed ID: 9616139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Maf expression in angioimmunoblastic T-cell lymphoma.
    Murakami YI; Yatabe Y; Sakaguchi T; Sasaki E; Yamashita Y; Morito N; Yoh K; Fujioka Y; Matsuno F; Hata H; Mitsuya H; Imagawa S; Suzuki A; Esumi H; Sakai M; Takahashi S; Mori N
    Am J Surg Pathol; 2007 Nov; 31(11):1695-702. PubMed ID: 18059226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human.
    Morito N; Yoh K; Fujioka Y; Nakano T; Shimohata H; Hashimoto Y; Yamada A; Maeda A; Matsuno F; Hata H; Suzuki A; Imagawa S; Mitsuya H; Esumi H; Koyama A; Yamamoto M; Mori N; Takahashi S
    Cancer Res; 2006 Jan; 66(2):812-9. PubMed ID: 16424013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
    Lombardi L; Poretti G; Mattioli M; Fabris S; Agnelli L; Bicciato S; Kwee I; Rinaldi A; Ronchetti D; Verdelli D; Lambertenghi-Deliliers G; Bertoni F; Neri A
    Genes Chromosomes Cancer; 2007 Mar; 46(3):226-38. PubMed ID: 17171682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-C chemokine receptor 1 expression in human hematolymphoid neoplasia.
    Anderson MW; Zhao S; Ai WZ; Tibshirani R; Levy R; Lossos IS; Natkunam Y
    Am J Clin Pathol; 2010 Mar; 133(3):473-83. PubMed ID: 20154287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
    Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
    Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
    Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
    Wang Y; Li Q; Xing S; Zhang H; Li D
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
    Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
    Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.
    Murase T; Ri M; Narita T; Fujii K; Masaki A; Iida S; Inagaki H
    Cancer Sci; 2019 Aug; 110(8):2600-2606. PubMed ID: 31218784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity.
    Asano K; Kikuchi K; Takehara M; Ogasawara M; Yoshioka Y; Ohnishi K; Iwata A; Shimizu S; Tanaka M
    Biochem Biophys Res Commun; 2023 Dec; 684():149135. PubMed ID: 37879249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
    Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
    Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
    Suzuki A; Iida S; Kato-Uranishi M; Tajima E; Zhan F; Hanamura I; Huang Y; Ogura T; Takahashi S; Ueda R; Barlogie B; Shaughnessy J; Esumi H
    Oncogene; 2005 Oct; 24(46):6936-44. PubMed ID: 16044163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of primary MAFB target genes in multiple myeloma.
    van Stralen E; van de Wetering M; Agnelli L; Neri A; Clevers HC; Bast BJ
    Exp Hematol; 2009 Jan; 37(1):78-86. PubMed ID: 19013005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and de novo follicular lymphoma.
    Vanasse GJ; Winn RK; Rodov S; Zieske AW; Li JT; Tupper JC; Tang J; Raines EW; Peters MA; Yeung KY; Harlan JM
    Mol Cancer Res; 2004 Nov; 2(11):620-31. PubMed ID: 15561778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4.
    Ho IC; Hodge MR; Rooney JW; Glimcher LH
    Cell; 1996 Jun; 85(7):973-83. PubMed ID: 8674125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.